Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004

AST-004Positive

AI Analysis

Summary

Astrocyte Pharmaceuticals secured $9.5 million in Series B funding to advance Phase 2 development of AST-004, a breakthrough cerebroprotective therapy for TBI and concussion. Enrollment is complete in the STARFAST sports-related concussion trial with topline results expected in winter 2026.

Clinical Trial Data

Phase

Phase 2

Outcome Details

$9.5 Million Series B funding secured

Importance:6/10

Sentiment:

0.85

Series B FundingPhase 2TBIConcussionClinical TrialEnrollment CompleteAST-004

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on September 30, 2026 10:00 AM

Read Original